Oncolytics Biotech (TSE:ONC) Hits New 12-Month Low – Time to Sell?

Oncolytics Biotech Inc. (TSE:ONC) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$1.03 and last traded at C$1.05, with a volume of 63494 shares. The stock had previously closed at C$1.05.

Analysts Set New Price Targets

Separately, Raymond James upgraded Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Trading Up 1.0 %

The business’s 50-day simple moving average is C$1.26 and its two-hundred day simple moving average is C$1.37. The firm has a market capitalization of C$81.47 million, a price-to-earnings ratio of -2.79 and a beta of 1.35. The company has a quick ratio of 8.86, a current ratio of 4.99 and a debt-to-equity ratio of 6.09.

Oncolytics Biotech (TSE:ONC) last issued its quarterly earnings results on Tuesday, November 12th. The company reported C($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C($0.11) by C($0.01). During the same period in the prior year, the firm posted ($0.14) EPS. Equities analysts forecast that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.